Translate Bio (NASDAQ:TBIO) Given a $17.00 Price Target at Citigroup

Citigroup set a $17.00 price target on Translate Bio (NASDAQ:TBIO) in a research report report published on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Translate Bio from a sell rating to a hold rating in a research report on Tuesday, July 16th. Jefferies Financial Group initiated coverage on shares of Translate Bio in a research note on Monday, July 22nd. They issued a buy rating and a $20.00 price target on the stock. HC Wainwright reaffirmed a buy rating and set a $21.00 price target on shares of Translate Bio in a report on Thursday, August 1st. Finally, Roth Capital began coverage on Translate Bio in a research report on Tuesday, June 18th. They set a buy rating and a $25.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $20.60.

Shares of TBIO traded up $0.46 during midday trading on Tuesday, hitting $10.27. 254,297 shares of the stock traded hands, compared to its average volume of 219,033. The business’s 50 day moving average price is $8.71 and its two-hundred day moving average price is $9.82. The firm has a market capitalization of $523.87 million, a PE ratio of -2.82 and a beta of 0.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 7.67 and a current ratio of 7.67. Translate Bio has a 1-year low of $4.81 and a 1-year high of $14.34.

Translate Bio (NASDAQ:TBIO) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.09). The firm had revenue of $1.17 million during the quarter, compared to analyst estimates of $1.73 million. Translate Bio had a negative return on equity of 84.22% and a negative net margin of 2,696.98%. As a group, equities research analysts forecast that Translate Bio will post -1.96 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of Montreal Can bought a new stake in shares of Translate Bio during the second quarter valued at about $31,000. Aevitas Wealth Management Inc. acquired a new stake in Translate Bio in the first quarter worth about $58,000. BNP Paribas Arbitrage SA acquired a new stake in Translate Bio in the first quarter worth about $63,000. Metropolitan Life Insurance Co NY bought a new position in Translate Bio in the 1st quarter valued at about $119,000. Finally, Susquehanna International Group LLP bought a new position in Translate Bio in the 2nd quarter valued at about $147,000. 72.68% of the stock is currently owned by institutional investors.

About Translate Bio

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

See Also: What are the risks of holding treasury bonds?

Analyst Recommendations for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.